Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients
- 24 August 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 33 (2), 273-276
- https://doi.org/10.1007/s10067-013-2378-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Infection relapse in spondyloarthritis treated with biological drugs: a single-centre studyScandinavian Journal of Rheumatology, 2012
- Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control studyClinical Rheumatology, 2011
- The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot studyClinical Rheumatology, 2011
- Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseasesAutoimmunity Reviews, 2008
- Safety of Cyclosporin A in HCV-Infected Patients: Experience with Cyclosporin A in Patients Affected by Rheumatological Disorders and Concomitant HCV InfectionAnnals of the New York Academy of Sciences, 2007
- Biologic agents and liver toxicity: an added concern or therapeutic opportunity?Nature Clinical Practice Rheumatology, 2007
- Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two casesClinical Rheumatology, 2006
- Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infectionJournal of the American Academy of Dermatology, 2006
- Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 casesJournal of the American Academy of Dermatology, 2004
- Tumor necrosis factor ? gene expression and the response to interferon in chronic hepatitis CHepatology, 1996